Is Juno worth a $10B-$12B buyout price? Analysts see megabucks deal in the making on reported Celgene talks
Just a week after bagging a blood cancer drug at the FDA’s threshold in a multibillion-dollar deal, Celgene is reportedly in talks to buy Juno Therapeutics in a move that would give it a major, late-stage effort on the CAR-T front.
The Wall Street Journal is reporting that sources close to the deal are telling them Celgene is in the hunt, and some analysts say that any final price could hit close to or even surpass the $10 billion mark.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
